Table 1.
Demographic data, clinical presentation and risk factors for extrahepatic portal vein obstruction in the study group
| n (%) | |
| Gender | |
| Male | 13 (43.3) |
| Female | 17 (56.7) |
| Ethnicity | |
| Jewish | 15 (50) |
| Arab | 14 (46.6) |
| Russian | 1 (3.3) |
| Referral | |
| Israeli | 19 (63.3) |
| Palestinian | 11 (36.7) |
| Gestational age | |
| Term | 23 (76.7) |
| Preterm | 7 (23.3) |
| Clinical presentation | |
| Splenomegaly | 13 (43.3) |
| UGI bleeding | 12 (40.0) |
| Cytopenia | 5 (16.6) |
| Elevated liver enzymes | 2 (6.6) |
| Risk factor for EHPVO | |
| Perinatal events | |
| Umbilical catheterization | 6 (20) |
| Omphalitis | 2 (6.6) |
| Sepsis, NEC | 1 (3.3) |
| Hypercoagulable state | |
| APLA syndrome | 2 (6.6) |
| Protein S and C deficiency | 1 (3.3) |
| MTHFR mutation homozygosity | 1 (3.3) |
| Unknown | 17 (56.6) |
EHPVO: Extrahepatic portal vein obstruction; UGI: Upper gastrointestinal; MTHFR: Methyltetrahydrofolate reductase; APLA: Anti phospholipid antibodies.